Form 4: Axogen Director John Johnson Receives Annual Equity Grant of 14,150 Restricted Stock Units

Axogen, Inc. Director John Johnson was granted 14,150 restricted stock units valued at $150,000 as part of his annual equity compensation, vesting on June 19, 2026.

Summary

• John Johnson, a Director of Axogen, Inc. (AXGN), reported the acquisition of 14,150 Restricted Stock Units (RSUs) on June 19, 2025.
• The RSUs represent a contingent right to receive one share of Axogen, Inc. common stock per unit.
• This grant is part of the annual equity compensation for his service on the Axogen, Inc. Board of Directors.
• The number of shares granted is based on a $150,000 valuation as of the grant date.
• The granted RSUs are scheduled to vest on June 19, 2026, which is the one-year anniversary of the grant date.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive sign of aligning management interests with shareholders and standard corporate governance. It does not indicate any negative or unexpected events.

Positives

• The equity grant aligns the Director's financial interests with those of the shareholders, encouraging long-term value creation.
• It represents a standard form of compensation for board service, indicating stable corporate governance practices.

Future Outlook

The 14,150 Restricted Stock Units granted to Director John Johnson are scheduled to vest on June 19, 2026, converting into common stock upon vesting.

Management Comments

• The equity grant is for 'service as Director on the Axogen, Inc. Board of Directors'.

Industry Context

This transaction is a routine disclosure of insider trading activity, specifically an equity grant, which is a common component of director compensation packages across publicly traded companies. It reflects standard practices for attracting and retaining qualified board members by aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• The granting of Restricted Stock Units (RSUs) as part of annual director compensation is a widely adopted practice among U.S. public companies, including those in the medical technology and biotechnology sectors like Axogen, Inc.
• The structure of the grant, with a one-year vesting period, is typical for annual equity awards to non-employee directors, aiming to incentivize continued service and align interests over a reasonable timeframe.
• While the specific valuation of $150,000 for an annual director equity grant can vary by company size, industry, and board responsibilities, it falls within a common range observed for directors of small to mid-cap companies.

Corporate Governance

Related Party Transactions

• The equity grant to Director John Johnson is a related party transaction, as he is an insider of Axogen, Inc. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant aligns the Director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The 14,150 Restricted Stock Units will vest on June 19, 2026, at which point they will convert into shares of Axogen, Inc. common stock.

Key Dates

Keywords

Axogen, AXGN, John Johnson, Restricted Stock Units, RSU, Equity Grant, Director Compensation, SEC Form 4, Insider Transaction